[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuropathy":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,73,97,126,151,181,205,231,253,279,306,348,374,396,430,456,478,501,528,550,573,596,623],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":53,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100270060","neurologic-stem-cell-treatment-study-100270060",false,"NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[54,55,31,32,56,57,45,58,36,51,48,59],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration","RECRUITING","2026-06-24",{"date":63,"type":64},"2026-06-26","ACTUAL",{"date":66,"type":64},"2016-06",{"date":68,"type":21},"2028-07-31",{"name":70,"class":71},"MD Stem Cells","INDUSTRY",3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":96},"100610463","phase-2-neuroguard-psilocybin-trial-for-preventing-chemo-induced-neuropathy-100610463","NCT07227909","NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy","Eligibility Criteria\n\n1. Participants with histologically or cytologically confirmed breast, colorectal, or head and neck cancer.\n2. Scheduled to receive platinum-based chemotherapy or taxanes (e.g., paclitaxel, docetaxel).\n3. Age 18 years or older\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n5. No pre-existing peripheral neuropathy greater than Grade 1 as defined by the NCI-CTCAE v5.0.\n6. No prior grade 3 AEs on current standard of care cancer treatment regimen\n7. Must have no major cognitive impairment and be oriented to person, place, and time (e.g. mini mental exam).\n8. Must demonstrate willingness to travel to MD Anderson Cancer center for all treatment and follow-up sessions, as well as consent to complete all evaluation instruments and assessments.\n9. Agree to abstain from any nicotine products for at least 8-12 hours prior to psilocybin administration until approximately 12 hours after (or when all post-session questionnaires have been completed, whichever comes earlier).\n10. Refrain from any psychoactive drugs (including alcohol) for 48 hours prior to psilocybin sessions and must refrain from psychoactive drugs 12 hours after psilocybin sessions. Must consent to urine drug screen (UDS) which will be given before receiving psilocybin. Participants with positive drug test will be retested (UDS) after 6 weeks and included if the repeated UDS is negative. Participant tested positive for a prescribed substance are eligible. Participant failing on the 2nd test (UDS) will be excluded.\n11. Must be free from any regularly scheduled psychotropic (antidepressant\u002Fanxiolytic class) medications for a minimum of 2 weeks prior to study. Intermittent or PRN use of short-acting anxiolytics or and anti-nausea medications (e.g., ondansetron) may be permitted as defined below in exclusionary criteria). Ondansetron could be taken but must be stopped at least 24 hours before psilocybin administration.\n12. Inhibitors of monoamine oxidase, UGT1A9, 1A10, and aldehyde or alcohol dehydrogenase should be discontinued 5 half-lives prior to active dose of psilocybin.\n13. Eligible subjects will have a third-party transportation by a licensed driver (e.g. friend, family or a driver) after the psilocybin session is complete. If a driver is used, a friend or family member must accompany them in the vehicle home\n14. Participants should agree to refrain from driving, operating heavy machinery, or engaging in safety-sensitive activities for the remainder of the day following psilocybin administration (for both 25mg or subperceptual 1mg placebo).\n15. Fluent in English\n\nExclusion Criteria\n\n1. History of another primary malignancy, except for:\n\n   1. Malignancy treated with curative intent and no active disease for ≥ 5 years before the first dose of study drug, with low potential risk for recurrence.\n   2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n   3. Adequately treated carcinoma in situ without evidence of disease.\n2. Clinically significant suicidality or high risk of completed suicide defined as:\n\n   1. Answer 'Yes' to C-SSRS Suicidal Ideation items 4 or 5 within the last 2 months at Screening or 'since last visit' at Baseline\n   2. Report having had any C-SSRS Suicidal Behavior item within the past 12 months at Screening or 'since last visit' at Baseline, as defined by 'Yes' to any of the following on the C-SSRS: actual attempt, interrupted attempt, aborted attempt, or preparatory acts\n   3. Have any suicidal ideation or thoughts, in the opinion of the study physician or PI, that presents a serious risk of suicidal or self- injurious behavior\n3. History of bipolar disorder, psychosis (including a history of schizophrenia).\n4. Persons with first-degree relatives who have schizophrenia or other psychotic disorders, or bipolar I or II disorder diagnosed by a qualified mental health professional.\n5. Functionally limiting comorbid conditions such as second primary malignancies in CNS or chest, and history of total laryngectomy or total glossectomy precluding them from communicating.\n6. ECG with QTc \\> 450.\n7. Participants with non-MRI compatible metal implants.\n8. Asymptomatic ALT or AST elevations \\>\u002F= 5X upper limit of normal, symptomatic ALT or AST elevations \\>\u002F= 2X upper limit of normal, or total bilirubin \\>\u002F= 2X upper limit of normal.\n9. Uncontrolled diabetes Mellitus with hemoglobin A1c \\> 8.5%\n10. The effects of psilocybin on the developing human fetus are unknown. For this reason, pregnant women will be excluded (Urine test for screening), women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstaining from intercourse with the opposite sex) prior to study entry and for the duration of study participation. This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following:\n\n    * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n    * History of hysterectomy or bilateral salpingo-oophorectomy.\n    * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n    * History of bilateral tubal ligation or another surgical sterilization procedure.\n\n    Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n11. Vulnerable populations, including children and cognitively impaired participants, will not be enrolled in this study.\n12. Participants with brain metastases.\n13. Risk for hypertensive crisis defined as Screening, Baseline, and Medication Session (day of dosing, prior to dosing) blood pressure \\>180\u002F120mmHG, HR \\>110 bpm. Of note, we will repeat vital signs for subjects with high initial reading and average three readings to determine eligibility criteria in such cases to account for normal variability in vital sign and \"white coat hypertension.\"\n14. Unstable medical conditions or serious abnormalities of complete blood count, chemistries, or ECG that in the opinion of the study physician would preclude safe participation in the trial.\n\n    Some examples include:\n    1. Uncompensated congestive heart failure\n    2. Clinically significant arrhythmias (e.g., ventricular fibrillation, torsades) or clinically significant ECG abnormality (i.e., QTC interval \\> 450)\n    3. Recent acute myocardial infarction or evidence of ischemia\n    4. Malignant hypertension\n    5. Congenital long QT syndrome\n    6. Acute renal failure\n    7. Severe hepatic impairment\n    8. Respiratory failure\n15. Significant central nervous system (CNS) pathology. Some examples include:\n\n    1. Primary or secondary cerebral neoplasm on imaging\n    2. Epilepsy and any history of seizure (regardless of if related to epilepsy) except for a onetime febrile seizure in childhood\n    3. History of stroke in the past 3 years\n    4. Untreated cerebral aneurysm\n    5. Dementia\n    6. Ongoing delirium of any kind (including with or without psychosis) in which subjects would not have the capacity to participate in the study.\n16. High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation.\n\n    Examples include:\n    1. Agitation\n    2. Violent behavior\n17. Active substance use disorders (SUDs) defined as: DSM-5 criteria for moderate or severe alcohol or drug use disorder (excluding caffeine and nicotine) within the past year\n\n    a. Extensive use of serotonergic hallucinogens (e.g., LSD, psilocybin) defined as: i. Any use in the last 12 months ii. \\>22 lifetime uses iii. History of diagnosed hallucinogen persisting perception disorder (HPPD)\n18. Concurrent Medications\n\n    1. Antidepressants\n    2. Centrally-acting serotonergic agents (e.g., MAO inhibitors)\n    3. Antipsychotics (e.g., first and second generation)\n    4. Mood stabilizers (e.g., lithium, valproic acid)\n    5. Aldehyde dehydrogenase inhibitors (e.g., disulfiram)\n    6. Significant inhibitors of UGT 1A0 or UGT 1A10\n    7. serotonin-acting dietary supplements (such as 5-hydroxytryptophan or St. John's wort)\n    8. efavirenz\n    9. Other Medications Listed in Section 3.1 19. Have a positive urine drug test including Amphetamines, Barbiturates, Buprenorphine, Benzodiazepines, Cocaine, Cannabis, Methamphetamine, MDMA, Methadone, Opiates (Morphine, Oxycodone), Phencyclidine (PCP), and Tetrahydrocannabinol (THC).\n\n    \u003C!-- -->\n\n    1. Note: Prescribed opiate medications (e.g., cancer-related pain) will be allowed to continue through the study period for participants who have been on a stable dose of such medicine for at least 1 month prior to Screening, as determined during review of concomitant medications.\n    2. Note: Prescribed benzodiazepine medications and nonbenzodiazepine sleeping medications will be allowed to continue through the study period for participants who have been on a stable dose of such a medicine for at least 6 weeks prior to Screening, as determined during review of concomitant medications.\n    3. Note: Participants using cannabis, including legal cannabis, for any purposes must agree to refrain from use beginning at Screening, as confirmed with a negative Baseline drug test, and through to the end of the study.\n    4. Note: Participants using prescribed psychostimulants (amphetamines and Ritalin), must agree to refrain from use 72 hours prior to dosing and until 12 hours after dosing.\n\n20\\. Have a psychiatric condition judged to be incompatible with establishment of rapport with the study therapists or safe exposure to psilocybin\n\n1. Have any psychological or physical symptom, medication or other relevant finding prior to randomization, based on the clinical judgment of the PI or relevant clinical study staff that would make a participant unsuitable for the study.\n2. Have an allergy or intolerance to any of the materials contained in either drug product Be enrolled in another clinical trial assessing intervention(s) for prevention or treatment of any pain-related symptoms",{"count":80,"type":21},83,[82],"PHASE2","To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study, psilocybin is being compared to standard supportive care and to a placebo.",[85,45],"Psilocybin","NOT_YET_RECRUITING","2026-06-22",{"date":61,"type":64},{"date":90,"type":21},"2026-11-04",{"date":92,"type":21},"2031-01-31",{"name":94,"class":95},"M.D. Anderson Cancer Center","OTHER",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100622976","a-study-of-neuropathy-caused-by-enfortumab-vedotin-in-people-with-urothelial-carcinoma-100622976","NCT07390617","A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma","Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic or Muscle-Invasive Urothelial Carcinoma Receiving Enfortumab Vedotin","Inclusion Criteria:\n\n* Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant.\n* Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires.\n* Age ≥ 18 years at the time of consent.\n* ECOG Performance Status of ≤ 3 within 28 days prior to consent.\n* Histological or cytologically confirmed urothelial carcinoma.\n* Patients must be planned to start systemic therapy with enfortumab vedotin\n* At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab\n\nExclusion Criteria:\n\nSubjects meeting any of the criteria below may not participate in the study:\n\n* Inability of the subject to understand and comply with study procedures.\n* Having previously received enfortumab vedotin\n* Students\u002Femployees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects).",{"count":105,"type":21},50,"OBSERVATIONAL","The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)",[45,109,110],"Urothelial Carcinoma","Metastatic Urothelial Carcinoma",[112,113,114,115,116],"urothelial carcinoma","metastatic urothelial carcinoma","neuropathy","Memorial Sloan Kettering Cancer Center","25-371","2026-05-26",{"date":119,"type":64},"2026-05-29",{"date":121,"type":64},"2026-01-20",{"date":123,"type":21},"2028-01-20",{"name":115,"class":95},7,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":72},"100378429","daily-hand-held-vibration-therapy-100378429","NCT04207437","Daily Hand-Held Vibration Therapy","Daily Hand-Held Vibration Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study","Inclusion Criteria:\n\n1. 18 years or older at enrollment\n2. Able to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization\n3. Have completed chemotherapy ≥ 60 days prior to enrollment\n4. Were exposed to neurotoxic chemotherapy with one or more of the following agents in the following doses: Paclitaxel (cumulative dose: ≥ 300 mg\u002Fm2) Docetaxel (cumulative dose: ≥ 100 mg\u002Fm2) Nab-paclitaxel (cumulative dose: ≥ 750 mg\u002Fm2) Oxaliplatin (cumulative dose: ≥ 510 mg\u002Fm2) Carboplatin (cumulative dose: ≥ 600 mg\u002Fm2) Cisplatin (cumulative dose: ≥ 200 mg\u002Fm2) Vincristine (cumulative dose: ≥ 4 mg\u002Fm2) Bortezomib (cumulative dose: ≥ 16 mg\u002Fm)\n5. Continue to display evidence of sensory CIPN in the hands rated at a Grade ≥ 2 according the National Cancer Institute's Common Toxicity Criteria-Adverse Events (NCI-CTC-AE, Version 5.0) Scale ≥ 60 days post-chemotherapy\n6. If solid tumor cancer, must have non-metastatic cancer\n7. Agree to return to clinic for required study related measurements at specified intervals\n\nExclusion Criteria:\n\n1. Have pre-existing neuropathy affecting the hands not related to chemotherapy (e.g., carpal tunnel syndrome, nerve compression, etc.)\n2. Known diagnosis of diabetes mellitus.\n3. Known contraindications for vibration therapy to hands, including deep venous thrombosis of the upper extremity or ongoing skin infection.\n4. Will be receiving concurrent radiation of the upper-extremity",{"count":134,"type":21},16,[24],"The purpose of this pilot study is to determine the safety and feasibility of a daily 3-minute hand-held vibration therapy intervention to reduce the severity of CIPN in the hands. The investigators hypothesize that daily vibration therapy can reduce the severity of patient's CIPN in their hands and improve CIPN-related quality of life. The hope is that results from this study will provide early data on the feasibility, efficacy, and most importantly, safety, of daily 3-minute hand-held vibration therapy needed to justify future clinical trials examining vibration therapy as a potential option for treating CIPN in the future.",[45,138,139,140],"Cancer","Chemotherapeutic Drug - Induced Nephropathy","Chemotherapeutic Toxicity",[45,142],"Vibration",{"date":144,"type":64},"2026-05-28",{"date":146,"type":64},"2021-12-06",{"date":148,"type":21},"2026-10",{"name":150,"class":95},"Indiana University",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":167,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":96},"100353441","balance-rehabilitation-with-modified-visual-input-in-patients-with-neuropathy-100353441","NCT03881930","Balance Rehabilitation With Modified Visual Input in Patients With Neuropathy","Balance REhabilitation With Modified Visual Input in Patients With acQuired Chronic Demyelinating Neuropathy and PROprioceptive Disorders","REQ-PRO","Inclusion Criteria:\n\n* Patients with chronic demyelinating acquired neuropathy\n* Age ≥ 18 years.\n* Patients able to walk 20 meters without human assistance at least indoors with or without technical assistance.\n* Patients with complaints such as discomfort, walking instability related to sensitivity disorders.\n* Patients being clinically stable for at least 2 months, regardless of ongoing treatments.\n* Patients who have provided consent.\n\nExclusion Criteria:\n\n* Patients unable to walk 20 metres without technical and human assistance indoors.\n* Patients with an ongoing hospitalization.\n* Patients already included and participating in another intervention study.\n* Patients with ongoing balance rehabilitation and continued during the REQ-PRO program in another rehabilitation centre or practice.\n* Patients with ongoing acute treatment (related to polyneuropathy) started less than 2 months ago or stopped less than 2 months ago.\n* Patients with scheduled surgery during the period of the patient's participation in the protocol, preventing the successful completion of the rehabilitation program and participation in assessments.\n* Patients with recent surgery, in particular lower limb prosthesis (less than 1 year old) or equipment contraindicated for planned exercises such as standing kneeling positions.\n* Patients with skin wounds on the foot that contraindicate rehabilitation.\n* Patients with balance disorders of vestibular origin or central neurological pathology.\n* Patients with a visual disability.\n* Patients with a hearing impairment that prevents the patient from hearing and understanding instructions during the rehabilitation program or assessments.\n* Patients with an inability to speak or understand the French language.\n* Patients with cognitive or language impairments that prevent understanding of the protocol.\n* Patients with a residence outside of the Paris Region (Ile de France).\n* Patients with a known pregnancy.\n* Patients not affiliated to a social security system (beneficiary or having a right), deprived of their right, under guardianship, curatorship, prisoner.",{"count":160,"type":21},40,[24],"This research focuses on the effects of rehabilitation on balance, in patients with acquired chronic demyelinating neuropathy. Rehabilitation will be performed with or without vision.\n\nIt is planned to include 40 subjects consulting for walking instability related to sensitivity disorders.\n\nThis multicenter study will take place in Paris's area. Each participant will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.\n\nThanks to randomization, patient will be allocated in one of the 2 following groups:\n\n* Control group, Patients will benefit from balance rehabilitation with open eyes.\n* Experimental group, they will perform the same exercises while keeping their eyes closed or their vision will be obstructed by a mask or disturbed by moving luminous dots projected on the environment in darkness.",[45,164,165,166],"Ataxia","Proprioceptive Disorders","Balance; Distorted",[168,169,165,170,171,172],"Peripheral neuropathy","Balance","Visual dependence","Rehabilitation","Physical Therapy",{"date":174,"type":64},"2026-05-27",{"date":176,"type":64},"2019-10-01",{"date":178,"type":21},"2027-11-01",{"name":180,"class":95},"Assistance Publique - Hôpitaux de Paris",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":187,"sex":17,"minAge":18,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":96},"100550146","pain-phenotyping-in-patients-with-neuropathic-pain-after-spinal-cord-injury-100550146","NCT06443281","Pain Phenotyping in Patients With Neuropathic Pain After Spinal Cord Injury","Inclusion Criteria:\n\n* Spinal injury cohort - general inclusion criteria:\n* Aged between 18-80 years\n* Traumatic and non-traumatic etiology\n* Para- and tetraplegic SCI\n* Complete and incomplete SCI\n* SCI with and without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* SCI since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* SCI since more than one year\n* Control cohorts with peripheral neuropathy:\n* General inclusion criteria:\n* Aged between 18-80 years\n* Neurological disorder affecting the peripheral nervous system (i.e., peripheral neuropathy)\n* Peripheral neuropathy with or without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* Peripheral neuropathy since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* Peripheral neuropathy since more than one year\n* Control cohorts without neuropathy \u002F healthy volunteers\n* General inclusion criteria:\n* Aged between 18-80 years\n* No medical condition affecting the peripheral and\u002For central nervous system (e.g., pain, systemic disease, psychological disorder)\n\nExclusion Criteria:\n\n* Inability to follow study instructions\n* Pregnancy\n* Medically manifested psychological disorder\n* Medical condition affecting the peripheral and\u002For central nervous system other than the desired experimental condition (e.g., additional peripheral neuropathy in the SCI cohort)",true,"80 Years",{"count":190,"type":21},300,"The development of neuropathic pain is one of the most debilitating sequels after a spinal cord injury (SCI). The overall aim of this study is to investigate potential underlying pathophysiological mechanisms of neuropathic pain after SCI. The functionality of the nociceptive pathway in humans as well as its plastic changes following SCI will be inferred with sophisticated sensory and pain phenotyping using quantitative sensory testing (i.e., psychophysical measures), objective neurophysiological measures of pain processing and the recording of pain-related autonomic responses (i.e., galvanic skin response, cardiovascular measures and pupil dilation). In addition, the interplay between the somatosensory and autonomic nervous system and its association with the development and maintenance of neuropathic pain after SCI will be investigated.",[193,194,195,45],"Spinal Cord Injuries","Pain, Neuropathic","Nociceptive Pain","2026-05-12",{"date":198,"type":64},"2026-05-15",{"date":200,"type":64},"2024-04-17",{"date":202,"type":21},"2030-04-30",{"name":204,"class":95},"University of Zurich",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":220,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100600323","nerve-excitability-in-cisplatin-induced-peripheral-neuropathy-100600323","NCT07095998","Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy","Evaluation of Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy","Inclusion Criteria Cohort A:\n\n* Adults age ≥ 18 who will begin cisplatin-based chemotherapy either alone or in combination with other agents that are not known to cause neuropathy.\n* Participants must have adequate hematologic parameters to allow chemotherapy.\n\nExclusion Criteria Cohort A:\n\n* Pre-existing peripheral neuropathy;\n* Family history of a genetic\u002Ffamilial neuropathy;\n* Any contraindication for treatment with cisplatin as determined by their primary oncologist;\n* Chemotherapy regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;\n* Patients with cardiac or spinal stimulating devices;\n* Women who are pregnant or breastfeeding;\n* Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;\n* Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;\n* Patients not considered to be able to comply with the protocol.\n\nInclusion Criteria Cohort B:\n\n* Adults age ≥ 18 with a diagnosis of cis-PN.\n* The last dose of cisplatin must be ≥ 3 months prior to study enrollment. Patients who may have been previously enrolled in Cohort A of this study are eligible to participate in Cohort B if they continue to have cis-PN symptoms 3 months after completion of cisplatin therapy.\n\nExclusion Criteria Cohort B:\n\n* Pre-existing peripheral neuropathy;\n* Family history of a genetic\u002Ffamiliar neuropathy;\n* History of cisplatin-based regimen combining cisplatin with another known chemotherapy agent that may cause peripheral neuropathy;\n* Patients with cardiac or spinal stimulating devices;\n* Women who are pregnant or breastfeeding;\n* Adults with impaired consent capacity as patients must be able to fill out questionnaires regarding their neuropathy symptoms;\n* Other medical conditions that in the opinion of the treating physician would make the protocol unreasonably hazardous for the patient;\n* Patients not considered to be able to comply with the protocol.",{"count":213,"type":21},60,[24],"This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.",[217,218,219,45],"Peripheral Neuropathy Due to Chemotherapy","Peripheral Neuropathy","Neurotoxicity Syndromes",[217,218,219,45],"2026-04-18",{"date":223,"type":64},"2026-04-22",{"date":225,"type":64},"2026-01-31",{"date":227,"type":21},"2028-12-31",{"name":229,"class":95},"Ka-Wai Ho",2,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":96},"100255924","whole-exome-sequencing-in-finding-causative-variants-in-germline-dna-samples-from-patients-with-peripheral-neuropathy-receiving-paclitaxel-for-breast-cancer-100255924","NCT02610439","Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer","Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples","Inclusion Criteria:\n\n* European American patients with DNA available and designated case or control\n* African American patients with DNA available and designated case or control status\n* Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European American (EA) peripheral neuropathy during their treatment with paclitaxel and who did not develop peripheral neuropathy following a full course of treatment with paclitaxel",{"count":239,"type":21},575,"This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.",[242,45],"Breast Carcinoma","2026-03-25",{"date":245,"type":64},"2026-03-27",{"date":247,"type":64},"2014-03-25",{"date":249,"type":21},"2100-01-01",{"name":251,"class":252},"National Cancer Institute (NCI)","NIH",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":262,"conditions":263,"keywords":266,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":96},"100442438","data-collection-of-standard-care-of-patients-in-the-emg-section-100442438","NCT05041387","Data Collection of Standard Care of Patients in the EMG Section","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* The patient or the patient's Legally Authorized Representative is capable of informed consent and signs the consent form.\n* Male or female, age 18 and over, no age limit\n* Possible neuromuscular disorder or neurodegenerative disorder.\n\nEXCLUSION CRITERIA:\n\nNo other exclusion criteria for patients","110 Years",{"count":261,"type":21},200,"Background:\n\nMost people who are referred to the EMG (Electromyography) Section of the NIH are enrolled into specific active studies. This allows researchers to learn about a range of rare neuromuscular disorders. But study criteria may not give researchers the chance to evaluate a single person or study a common symptom. Therefore, researchers want to assess people with neuromuscular disorders who are not currently enrolled in any NIH studies. They will perform tests on these individuals in the EMG Lab. Then they will create a repository of data that may be used for future research. This will help them learn more about these disorders.\n\nObjective:\n\nTo retain data that is collected as part of participant visits to the NIH.\n\nEligibility:\n\nPeople aged 18 and older who will be visiting the NIH for evaluation of their neuromuscular disorder.\n\nDesign:\n\nParticipants will be screened with a medical record review.\n\nParticipants will have a physical exam. They will be evaluated for their neuromuscular disorder. They may have tests to learn more about how their nerves and muscles work that are called nerve conduction and EMG studies. Their muscles and nerves may be assessed with an ultrasound. Their ability to sweat may be measured. Their heart rate and blood pressure may be taken. Changes to their breathing or changes in their body position may be measured.\n\nParticipant data will be given a unique numerical identifier that can be used if the data is shared. Data will be stored on a server and in a database.\n\nParticipants will have 1-2 visits. Each visit will last less than 4 hours. They may be contacted for a follow-up visit.",[45,264,265],"Muscle Disorders","Dysautonomia",[267,268,269],"Standard of Care","Screening","NEUROMUSCULAR DISORDERS","2026-03-07",{"date":272,"type":64},"2026-03-10",{"date":274,"type":64},"2024-06-24",{"date":276,"type":21},"2031-05-01",{"name":278,"class":252},"National Institute of Neurological Disorders and Stroke (NINDS)",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":96},"100626619","collection-of-demographic-clinical-and-instrumental-data-of-patients-with-peripheral-neuropathy-including-neurological-examination-data-peripheral-nerve-conduction-analysis-and-nerve-electromyography-and-ultrasound-100626619","NCT07437989","Collection of Demographic, Clinical, and Instrumental Data of Patients With Peripheral Neuropathy Including Neurological Examination Data, Peripheral Nerve Conduction Analysis, and Nerve Electromyography and Ultrasound).","An Observational Prospective Study on Patients With Peripheral Neuropathies Explored With a Combined Clinical, Neurophysiological and Nerve Ultrasound Approach- REG-NP","REG-NP","Inclusion Criteria:\n\n1. Adult patients (age ≧ 18 years old) able to give consent\n2. Diagnosis of peripheral nerve disorder\n\nExclusion Criteria:\n\n1\\. The patient is unable to consent for him\u002Fherself",{"count":288,"type":21},4000,"The study involves recording personal, clinical, and instrumental information. The acquisition of the above-mentioned personal and clinical information will be carried out in conjunction with the usual follow-up visits scheduled as part of normal clinical practice. At the end of the study, a statistical analysis of the data will be carried out.",[45],[292,293,294,295,296],"ultrasound","peripheral nervous system","Neurological","Electrodiagnostic","Neuromuscolar ultrasound","2026-02-20",{"date":299,"type":64},"2026-02-27",{"date":301,"type":64},"2025-02-23",{"date":303,"type":21},"2035-02",{"name":305,"class":95},"Casa di Cura Dott. Pederzoli",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":313,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":315,"conditions":316,"keywords":325,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":347},"100580429","studying-the-presence-of-cfrd-complications-with-thoughtful-recruitment-spectrum-100580429","NCT06837181","Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)","SPeCTRuM","Inclusion Criteria:\n\n* Written informed consent (and assent when applicable) obtained from participant or participant's legally authorized representative\n* For Adults: Must be able to consent on one own's behalf (i.e., cannot lack cognitive capacity to consent due to the required patient-reported outcomes)\n* Be willing and able to adhere to the study protocol requirements\n* Age ≥ 12 years at time of enrollment\n* CF diagnosis based on two CF causing mutations and\u002For positive sweat test according to CFF diagnostic criteria\n* CFRD diagnosis ≥ 5 years at time of enrollment\n\nExclusion Criteria:\n\n* History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject\n* History of transplant\n* Pregnancy reported by participant at time of consent or at any point during active study participation\n\nPulse Wave Velocity Exclusion Criteria:\n\n* Erratic, accelerated or mechanically controlled irregular heart rhythms including arrhythmias\n* Carotid or aortic valve stenosis\n* Peripheral artery disease or leg artery disease\n* Generalized constriction or localized spasm of muscular conduit arteries such as seen immediately after hypothermic cardiopulmonary bypass surgery or accompanying Raynaud's phenomena or intense cold.\n* Possible exclusions based on investigator medical provider assessment (additional precautions may be followed to allow inclusion):\n\n  * Pressure reading should not be conducted on a limb where there is intravenous access, arterio-venous shunt, or where circulation is compromised.\n  * Pressure reading should not be conducted on the side of the body that a mastectomy was done.","12 Years",{"count":261,"type":21},"This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF.\n\nThe overall Aim is to describe prevalence of diabetes microvascular complications and macrovascular surrogates in people with established CFRD.",[317,318,319,320,45,321,322,323,324],"Cystic Fibrosis (CF)","Cystic Fibrosis-related Diabetes","Diabetes","Retinopathy","Nephropathy","Blood Pressure","Cardiovascular Risk","Microvascular",[326,327,328,329,330,331,332,319,333,334,335,336,337],"Cystic Fibrosis","CFRD","Cystic Fibrosis-Related Diabetes","Observational","Physical Activity Tracker","Continuous glucose monitoring","CGM","blood pressure","cardiovascular risk","microvascular","diabetes complications","social determinants of health","2026-02-09",{"date":340,"type":64},"2026-02-10",{"date":342,"type":64},"2025-09-18",{"date":344,"type":21},"2028-11-30",{"name":346,"class":95},"Jaeb Center for Health Research",18,{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":96},"100415252","diabetic-neuropathy-in-spinal-cord-stimulator-patients-100415252","NCT04687215","Diabetic Neuropathy in Spinal Cord Stimulator Patients","Spinal Cord Stimulation Improves Pain, Arterial Stiffness and Vascular Flow in Lower Extremities in Patients With Diabetes Mellitus Type II A Multidisciplinary Collaborative Prospective Study","Inclusion Criteria:\n\n1. Patients with DM type 2 of more than 1-year duration\n2. DM stage 3 or less\n3. Patients ≥18 years of age\n4. Refractory painful diabetic peripheral neuropathy of the lower extremities\n5. ABI index \\\u003C0.9\n\nExclusion Criteria:\n\n1. Patients on anticoagulants\n2. Patients with active infections\n3. Patients with HbA1\\>10\n4. Psychiatric disorders and cognitive dysfunctions\n5. Illicit Drug Usage\n6. Patients on dialysis\n7. BMI\\>35.0\n8. Surgery within the last 30 days\n9. Ulcer of the lower extremities\n10. Calcification of the peripheral arteries",{"count":356,"type":21},25,"The objective of this study is to assess the effect Spinal Cord Stimulators have toward improving vascular changes of diabetes mellitus in patients eligible for SCS placement based on their condition of painful diabetic neuropathy; we will evaluate improving their disability and quality of life, improving micro-circulatory changes induced by Diabetes Mellitus (DM), improving macro-circulatory changes induced by DM and improving arterial stiffness of the vessels of the lower extremity.",[359,45,360,361,362,363,364],"Diabetes Mellitus","Neuropathic Pain","Vascular Diseases","Vascular Stiffness","Microvascular Changes","Pain, Chronic","2026-02-03",{"date":367,"type":64},"2026-02-05",{"date":369,"type":64},"2022-01-27",{"date":371,"type":21},"2026-12-01",{"name":373,"class":95},"University of Chicago",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":382,"conditions":383,"keywords":386,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":96},"100622950","efficacy-of-transcutaneous-pulsed-radiofrequency-in-postherpetic-neuralgia-100622950","NCT07390279","Efficacy of Transcutaneous Pulsed Radiofrequency in Postherpetic Neuralgia","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of postherpetic neuralgia (PHN)\n* No invasive or noninvasive treatment related to PHN (e.g., capsaicin, lidocaine patches) within the past 3 months\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Patients with a cardiac pacemaker\n* Known allergy to transcutaneous electrode pads\n* Active skin infection at the pad application site\n* Presence of a metallic implant in the treatment area\n* Circulatory disorders or skin lesions at the treatment site\n* Inability to maintain appropriate positioning\n* Inability to communicate effectively\n* Presence of psychosis or progressive neurological deficits\n* Pregnancy",{"count":381,"type":21},35,"Postherpetic neuralgia (PHN) is a chronic pain syndrome that may be resistant to treatment and can lead to physical and social disability as well as psychological disturbances, persisting for years in some patients. Varicella zoster virus remains latent in the sensory neurons of individuals who have previously had chickenpox. Reactivation of the latent virus results in herpes zoster. Herpes zoster typically begins with dermatomal pain, followed within a few days by the development of characteristic dermatomal skin rashes. These cutaneous lesions usually resolve within 2-4 weeks; however, pain may persist even after the rash has healed.\n\nThere is variability in the literature regarding the definition of PHN. The development of PHN is associated with increased central neuronal sensitization, reduced inhibitory neuronal function, inflammation and nerve injury in the peripheral nervous system, and abnormal neural transmission following nerve damage. PHN is the most common complication of herpes zoster and occurs in approximately 9-19% of affected patients. Its incidence increases with age, occurring in about 2% of patients under 50 years of age, approximately 20% of those over 50 years, and nearly 35% of patients over 80 years of age.\n\nVarious treatment options are available for the management of PHN-related pain, including pharmacological and interventional approaches. Systemic agents include tricyclic antidepressants, calcium channel alpha-2-delta ligands, serotonin-norepinephrine reuptake inhibitors, and opioids, while topical treatments include lidocaine and capsaicin. Interventional treatment options for PHN include epidural and intrathecal injections, sympathetic nerve blocks, erector spinae plane block, subcutaneous injections, and spinal cord stimulation.",[384,385,45],"Postherpetic Neuralgia","Chronic Pain",[387],"postherpetic neuralgia","2026-01-28",{"date":367,"type":64},{"date":391,"type":21},"2026-02-01",{"date":393,"type":21},"2026-08-03",{"name":395,"class":95},"Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization",{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":405,"conditions":406,"keywords":409,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":96},"100578130","feasibility-testing-of-a-tai-chi-program-for-chemotherapy-induced-peripheral-neuropathy-treatment-tct-100578130","NCT06807294","Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)","Inclusion Criteria:\n\n* Age 18 years old and older\n* Cancer survivors with no evidence of disease (cancer);\n* Completed neurotoxic chemotherapy, i.e., platinum agents, taxanes, vinca alkaloids, and bortezomib, at least three months before enrollment;\n* A CIPN diagnosis based on symptom history, loss of deep tendon reflexes, or presence of symmetrical stocking-glove pain, numbness, or paresthesia;\n* Answers \"yes\" to the following question: \"Do you feel as though your balance is affected from experiencing CIPN?\" or \"Are you afraid of falling as a result of your CIPN?\";\n* On a stable regimen (no change in past three months) if taking anti-neuropathy or other pain medications;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤ 2\n* Willing to adhere to all study-related procedures, including randomization to the Tai Chi or waitlist group, 2 in-person visits to Dana-Farber Cancer Institute (DFCI) (one within 2 weeks of enrollment and one at week 12);\n* Willing to adhere to requirement that no new pain medication be taken throughout the study period; and\n* Individuals receiving endocrine therapy or targeted\u002Fantibody therapy, such as trastuzumab, pertuzumab, or immunotherapy, will be eligible to participate.\n\nExclusion Criteria:\n\n• Patients who have received physical therapy or Tai Chi training, specifically for CIPN, in the past three months.",{"count":403,"type":21},21,[24],"This research is being done to determine whether a 12-week virtual Tai Chi training program, designed to improve balance and small nerve fiber function, is feasible and acceptable among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).",[407,217,408,45],"Chemotherapy Induced Peripheral Neuropathy (CIPN)","Peripheral Neuropathies",[218,410,411,412,413,414,415,416,417,418,419,420],"Chemotherapy Induced Peripheral Neuropathy","Cancer survivor","CIPN","Tai Chi","Balance training","Falls prevention","Non-pharmacological intervention","Mind-body exercise","Quality of life","Feasibility study","Pilot study","2026-01-27",{"date":423,"type":64},"2026-01-29",{"date":425,"type":64},"2026-01-16",{"date":427,"type":21},"2026-10-31",{"name":429,"class":95},"Dana-Farber Cancer Institute",{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":17,"minAge":437,"maxAge":18,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":440,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":96},"100615053","phase-3-glutamine-for-the-prophylaxis-of-vincristine-induced-neuropathy-in-children-and-adolescents-with-cancer-100615053","NCT07287592","Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.","Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer. A Single Center Study","Inclusion Criteria:\n\n1. No sex predilection.\n2. Age: 6 years to 18 years\n3. Children and adolescents diagnosed with hematological malignancy or solid tumors expected to receive a cumulative dose of 6 mg\u002Fm2 of VCR over a 12 week period (or \\>6 mg\u002Fm2 if individual VCR doses were capped at 2 mg) according to their primary cancer treatment protocol\n4. Patients with score less than 5 on pediatric modified total neuropathy scale at Time 0\n\nExclusion Criteria:\n\n1. Patients with CNS tumors\n2. Patients with focal neurologic findings or CNS metastasis Patients with premorbid developmental disorders, neuromuscular disorders or diabetes mellitus Patients with recurrent disease already exposed to \\>8 mg\u002Fm2 of VCR Patients with score more than 5 on pediatric modified total neuropathy scale","6 Years",{"count":439,"type":21},70,[441],"PHASE3","The goal of this clinical trial is to assess the efficacy of glutamine in preventing the occurrence of vincristine induced neuropathy and to compare the reduction in rate of any dose reductions and premature chemotherapy discontinuation rates due to peripheral neuropathy between those who treated with glutamine and those who did not.\n\nParticipants will:\n\nreceive glutamine in a dose of 6 g \u002Fm2 twice daily (up to a maximum of 10 g\u002Fdose) for 14 consecutive days from d 1 of induction and 14 days from d1 of continuation .\n\n• Subjects will be asked to return for a complete study assessments visit every 14-days during supplementation period for a total of 4 visits Keep a diary of their symptoms of neuropathy and compliance to treatment and any adverse event",[45,138],[445,446,114],"vincristine","cancer","2025-12-14",{"date":449,"type":64},"2025-12-17",{"date":451,"type":21},"2025-12-30",{"date":453,"type":21},"2027-04-30",{"name":455,"class":95},"Ain Shams University",{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":463,"targetDuration":465,"studyType":106,"phases":4,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":96},"100270778","establishing-normative-data-for-pupillometer-assessments-in-neuro-intensive-care-100270778","NCT02804438","Establishing Normative Data for Pupillometer Assessments in Neuro-Intensive Care","ENDPANIC","Inclusion Criteria:\n\n* Data will be collected on patients admitted to enrolling hospitals who have been assigned, by the attending physician, to have regular pupillary assessments, and in whom staff nurses are performing pupillary assessments with the pupillometer.\n\nExclusion Criteria:\n\n* Out-patients\n* Patients that do not have orders for regular pupillary assessments",{"count":464,"type":21},1000,"6 Months","The purpose of this study is to collect a large amount of data that may assist in addressing the gap in knowledge of understanding pupillometer readings using a pupillometer device.\n\nThe aim of this project is to establish normative values for pupillometer data. Measures of central tendency will be developed for the variables provided by automated pupillary exams, which will provide an enhanced understanding of clinically appropriate pupil values for size, reactivity, and neurological pupil index.",[468,45],"Critical Illness","2025-10-18",{"date":471,"type":64},"2025-10-22",{"date":473,"type":64},"2015-07",{"date":475,"type":21},"2028-09",{"name":477,"class":95},"University of Texas Southwestern Medical Center",{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":17,"minAge":485,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":96},"100586228","clinical-efficacy-of-the-erchonia-evrl-for-providing-temporary-relief-of-idiopathic-peripheral-neuropathy-foot-pain-100586228","NCT06912646","Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain","An Evaluation of the Effect of the Erchonia® EVRL™ for Prescription Home Use Application in Providing Temporary Relief From Idiopathic Peripheral Neuropathy Foot Pain","Inclusion Criteria:\n\n* Previously diagnosed with idiopathic peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months.\n* Over the age of 22 years of age\n* Able to read and write English\n* Constant feet pain on-going over at least the past 3 months\n* Subjects using analgesics (pain medication) must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14 days prior to study enrollment; and be willing and able to not have planned upward dose titration of analgesics during the study period. Decreasing frequency of analgesic use during the study is permitted. Cannabis prescribed for medicinal purposes qualifies as an analgesic in this context\n* Willing and able to refrain from engaging in any non-study therapies for the management of foot pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy, hot or cold packs, and alternative therapies such as chiropractic care and acupuncture\n* Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6 hours before a scheduled VAS foot pain rating is to be recorded\n* Subject's degree of foot pain on the 0-100 VAS, with \"0\" being no pain and \"100\" being worst pain imaginable, is 50 or greater\n\nExclusion Criteria:\n\n* Diabetic, referred to as having hemoglobin A1c (HbA1C) of 6.5% or higher\n* Previously diagnosed with any definitive (i.e. not idiopathic) cause of peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months, such as diabetes, injury, infection, toxins and poisons, alcoholism, medications such as chemotherapy, autoimmune disorders, etc..\n* Pregnant or possibly pregnant, breastfeeding, or planning pregnancy during the intended course of study participation\n* Open wounds (sores, cuts, ulcers, etc.) on or around the treatment area on the feet\n* Cancerous growths or lesions on or around the treatment area on the feet\n* Difficulty with hand dexterity sufficient to negatively impact the ability to administer treatments with the laser such as from severe arthritis in the hands, Multiple Sclerosis, Cerebral Palsy, Parkinson's Disease, Huntington's Disease, etc.","22 Years",{"count":487,"type":21},32,[24],"The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic neuropathy foot pain in individuals diagnosed with idiopathic neuropathy by a suitably qualified and licensed health professional.",[45,491],"Neuropathy;Peripheral","2025-09-05",{"date":494,"type":64},"2025-09-08",{"date":496,"type":64},"2025-05-01",{"date":498,"type":21},"2027-06-16",{"name":500,"class":71},"Erchonia Corporation",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":17,"minAge":313,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":96},"100378536","ivig-for-drug-and-device-refractory-gastrointestinal-auto-immune-neuropathy-100378536","NCT04208828","IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy","GAIN","Inclusion Criteria: Patient with otherwise refractory symptoms of gastrointestinal (GI) motor disorders.\n\n\\-\n\nExclusion Criteria: Inability to receive intravenous immunoglobulin.\n\n\\-","90 Years",{"count":510,"type":21},400,"Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions\u002F Some of these patients have serologic and\u002For endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.",[513,514,45],"Gastrointestinal Motility Disorder","Gastroparesis",[514,516,517,518,45],"Nausea","Vomiting","Abdominal Pain","2025-07-29",{"date":521,"type":64},"2025-08-01",{"date":523,"type":64},"2020-01-02",{"date":525,"type":21},"2028-01-02",{"name":527,"class":95},"University of Louisville",{"id":529,"slug":530,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":72},"100578931","evaluation-of-urinary-dysfunction-in-canvas-patients-100578931","NCT06817707","Evaluation of Urinary Dysfunction in CANVAS Patients","UROCANVAS","Inclusion Criteria:\n\n* 18 years old and more\n* genetic confirmation of CANVAS (presence of pathogenic penta nucleotide expansion in both alleles of the replication factor C subunit 1(RFC1) gene or pathological penta nucleotide expansion in the heterozygous state associated with a truncating mutation on the second allele of the RFC1 gene)\n* Able to undergo renovesical ultrasound and urinary flow measurement;\n* Having given informed consent in writing;\n* Negative pregnancy test for people on childbearing age;\n* Social security affiliated\n\nExclusion Criteria:\n\n* Presenting another urological pathology of base, not related to CANVAS;\n* Having undergone a urological intervention within the 6 months preceding the screening visit;\n* Presenting a condition that is incompatible with the proper conduct of the study as determined by the physician;\n* Protected by law under guardianship or curators, or not able to participate in a clinical study pursuant to article L. 1121-16 of the French Public Health Code\n* Pregnant or breastfeeding women for women of childbearing age",{"count":160,"type":21},[24],"The investigator wishes to evaluate the prevalence of urinary symptoms in patients diagnosed with Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS).\n\nAs much as one third of patients living with CANVAS experience symptoms of urinary system dysfunction. The primary objective of this study is to evaluate the incidence of urinary symptoms in these patients, as well as the potential complications that might occur at the level of the upper and lower urinary system. The investigator also wishes to analyse the connection between the severity of the neurological deficits, the presence of dysautonomia and the presence of urinary dysfunction. To that end, the data collected in the study will concern : a detailed neurological examination including SARA (Scale for the assessement and rating of ataxia) scale assessement, laboratory tests of the renal function, dysautonomia tests with Sudoscan and research of orthostatic hypotension, urinary function questionnaires, dysautonomia questionnaire, urodynamic tests and urinary system ultrasound.",[539,45,540],"Cerebellar Ataxia","Vestibular Areflexia","2025-03-25",{"date":543,"type":64},"2025-03-26",{"date":545,"type":64},"2025-03-21",{"date":547,"type":21},"2027-03",{"name":549,"class":95},"Centre Hospitalier Universitaire de Nice",{"id":551,"slug":552,"hasResults":11,"nctId":553,"briefTitle":554,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":96},"100573006","neuromuscular-complications-of-mek-inhibitors-a-french-case-series-and-a-systematic-review-of-the-literature-100573006","NCT06740656","Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature","Inclusion Criteria:\n\n* Patients with neuromuscular complications of MEK inhibitors used alone or in combination\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* Refusal of data collection",{"count":557,"type":21},5,"MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors.\n\nWith the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis.\n\nYet, so far, these complications have only been documented in a few single case reports.\n\nOur aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.",[560,561,45,562,563],"Myositis","Myasthaenia Gravis","Guillain Barré Syndrome","Parsonage Turner Syndrome","2025-02-16",{"date":566,"type":64},"2025-02-18",{"date":568,"type":21},"2025-03-01",{"date":570,"type":21},"2026-01-01",{"name":572,"class":95},"Central Hospital, Nancy, France",{"id":574,"slug":575,"hasResults":11,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":187,"sex":17,"minAge":18,"maxAge":188,"enrollmentInfo":580,"targetDuration":4,"studyType":22,"phases":581,"briefSummary":582,"conditions":583,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":96},"100476429","multisensory-stimulation-to-target-sensory-loss-and-chronic-pain-in-neuropathic-patients-100476429","NCT05483816","MultiSENSory Stimulation to TArgeT Sensory Loss and ChronIc Pain in NeurOpathic PatieNts","SENSATION","for healthy:\n\n* Inclusion:\n\n  * Age 18-80\n  * Visual acuity\\>6 on Snellen visual acuity chart\n* Exclusion:\n\n  * Pregnancy\n  * Cognitive deficits (Mini Mental State Examination\\<23)\n  * Cyber-sickness\n  * Prior or current psychological diseases\n  * Pacemakers\n  * Epilepsy\n  * Claustrophobia\n  * Other MRI contraindications\n  * Unhealed fractures\n  * Unhealed wounds\n  * Cancerous growth in proximity to feet\n  * Swollen, infected or inflamed areas on feet or skin eruptions on feet such as phlebitis, thrombophlebitis or varicose veins\n\nfor patients:\n\n* Inclusion:\n\n  * Age 18-80\n  * Visual acuity\\>6 on Snellen visual acuity chart\n  * Diagnosis of peripheral neuropathy\n  * Pain in lower limbs\\>=3 cm on VAS scale\n* Exclusion:\n\n  * Pregnancy\n  * Relevant comorbidities that would affect the outcomes of the study (by judgement of physicians)\n  * Ulcers\n  * Cognitive deficits (Mini Mental State Examination\\<23)\n  * Cyber-sickness\n  * Prior or current psychological diseases\n  * Pacemakers\n  * Epilepsy\n  * Claustrophobia\n  * Other MRI contraindications\n  * Unhealed fractures\n  * Unhealed wounds\n  * Cancerous growth in proximity to feet",{"count":160,"type":21},[24],"Neuropathy is a costly and disabling health issue, which consists of a degeneration of the peripheral nerves. Even though the causes may be different, such as diabetes or amputation, the consequences for neuropathic patients are multiple and extremely debilitating. Among the alarming symptoms it implicates, chronic pain and sensory loss are among the most severe ones. Because of the loss of sensations, patients are forced to have an altered gait strategy, an impaired balance and a fivefold increased risk of falling. Furthermore, since they lose sensations and feel numbness in their extremity, they are discouraged in walking, hence leading to a sedentary lifestyle. All of this is worsened by the development of neuropathic pain, which has a high comorbidity with psychological issues, such as depression and anxiety.\n\nToday, proper treatments for neuropathic pain that exclude pharmacological solutions are still missing. This is due to the complexity of the neurobiological mechanisms underlying the origin of neuropathy, the multifaceted physical and psychological nature of pain and the lack of reliable biomarkers.\n\nThe aim of this project is to tackle the major problems connected to neuropathy thanks to non-invasive stimulation of the peripheral nervous system. The system is composed of an insole with pressure sensors that captures in real time the force exerted by the subject on the foot and couples this information with parameters of electrical stimulation. Thanks to optimal electrode placement and intensity modulation, subjects are able to perceive in real-time in a somatotopic manner (i.e., under their foot) how they are walking. The aim now is twofold: first the investigators want to couple this stimulation with Virtual Reality (VR) to develop a neuroadaptive non-invasive brain computer interface (BCI) to treat pain and secondly the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain. Finally, the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain.",[45,584,585,46,586],"Neuropathy, Painful","Sensory Neuropathy","Amputation","2024-11-14",{"date":589,"type":64},"2024-11-18",{"date":591,"type":64},"2022-06-30",{"date":593,"type":21},"2028-02-28",{"name":595,"class":95},"ETH Zurich",{"id":597,"slug":598,"hasResults":11,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":604,"conditions":605,"keywords":608,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":96},"100193015","mri-guided-cryoablation-to-alleviate-pain-in-head-neck-and-spine-100193015","NCT01788410","MRI-Guided Cryoablation to Alleviate Pain in Head, Neck and Spine","MRI-Guided Cryoablation of Head, Neck and Spine Nerves and Facets Using the Advanced Multimodality Image Guided Operating(AMIGO) Suite","Inclusion Criteria:\n\n* Participants must be willing and able to sign a written informed consent document.\n* Patients must have facet joint disease or pain due to a damaged or compressed nerve that would benefit from a minimally invasive image-guided procedure (i.e., adjacent to critical structures, better visualized under 3 Tesla MRI than CT)\n* Subjects must be able to adhere to the visit schedules and attend pre and post imaging.\n* Participants must be at least 18 years of age\n* Participants must have an estimated life expectancy of \\>8 weeks in the opinion of the clinician.\n\n  * Patients with radiculopathy must have the cause of pain confirmed by a nerve block within 3 months prior to ablation\n\nExclusion Criteria:\n\n* Contraindications to MRI and Gadolinium- (i.e. estimated Glomerular Filtration Rate \\\u003C60ml\u002Fmin, metal clips)\n* Pregnant or breastfeeding woman are excluded from this research.",{"count":105,"type":21},"The objective of this study is to provide pain relief to patients with facet joint disease or head and neck pain related to compression of a nerve root. The goal is to provide palliative care with superior efficacy and longer relief compared to current methods.",[606,45,607],"Facet Joints; Degeneration","Neuralgia",[609,610,611,612,607,45,613],"Cryoablation","Nerves","Facet joint","Pain","Image-guided","2023-08-07",{"date":616,"type":64},"2023-08-08",{"date":618,"type":4},"2013-05",{"date":620,"type":21},"2030-05",{"name":622,"class":95},"Brigham and Women's Hospital",{"id":624,"slug":625,"hasResults":11,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":187,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":22,"phases":631,"briefSummary":632,"conditions":633,"keywords":641,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":96},"100315776","evaluation-of-outcomes-with-umbilical-cord-allograft-for-musculoskeletal-conditions-musculoskeletal-conditions-100315776","NCT03390920","Evaluation of Outcomes With Umbilical Cord Allograft for Musculoskeletal Conditions Musculoskeletal Conditions","Evaluation of Regenerative Medicine Outcomes With Umbilical Allograft for Musculoskeletal Conditions","Inclusion Criteria:\n\n1. Age 18 and over.\n2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.\n\n4\\) Competent to understand the study protocol and provide voluntary informed consent.\n\nExclusion Criteria:\n\n1. Active Infection\n2. Pregnancy, Lactating\n3. Clotting disorder",{"count":261,"type":21},[24],"The aim of the study is to determine the efficacy of an Amniotic Fluid Tissue Product for pain relief and functional improvements for all types of musculoskeletal conditions. The study is prospective, with outcome measures being obtained at numerous time points after the regenerative procedure.",[634,635,636,637,638,639,45,640],"Osteoarthritis","Tendinitis","Sports Injury","Degenerative Disc Disease","Degenerative Arthritis","Ligament Injury","Pelvic Pain",[642,643,644,645,646,647],"regenerative medicine","arthritis","amniotic","stem cell","growth factor","cartilage","2021-09-10",{"date":650,"type":64},"2021-09-17",{"date":652,"type":21},"2022-01-01",{"date":654,"type":21},"2030-01-01",{"name":656,"class":71},"R3 Stem Cell"]